| (2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride | IC50 | 106.0 [1] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | IC50 | 210.0 [1], 3100.0 [2] |
| 4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide | Ki | 1200.0 [1] |
| Marimastat | IC50 | 4.1 [1], 11.0 [2], 20.0 [3], 10000.0 [4] |
| Prinomastat | IC50 | 54.0 [1], 72.0 [2], 91.0 [3] |
| Prinomastat | Ki | 54.0 [1] |
| N-(3-Methoxybenzyl)-4-Oxo-3,4-Dihydroquinazoline-2-Carboxamide | IC50 | 10000.0 [1] |
| 2-((4-Phenoxyphenylsulfonyl)methyl)thiirane | Ki | 96000.0 [1] |
| CID 6914621 | Ki | 259.0 [1] |
| Mmp inhibitor II | IC50 | 30.0 [1] |
| Mmp inhibitor II | Ki | 30.0 [1] |
| (2S)-2-[[4-(4-Methoxyphenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 7200.0 [1], 10000.0 [2] |
| Benzyl 6-Benzyl-5,7-Dioxo-6,7-Dihydro-5h-[1,3]thiazolo[3,2-C]pyrimidine-2-Carboxylate | IC50 | 30000.0 [1], 100000.0 [2] |
| Batimastat | IC50 | 2.4 [1], 6.0 [2] |
| N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)acetamide | IC50 | 50000.0 [1] |
| N-[(2S)-1-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-N-hydroxyformamide | IC50 | 10000.0 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 7000.0 [1] |
| N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | Ki | 7000.0 [1] |
| 4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic Acid | IC50 | 30000.0 [1] |
| (3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]benzoyl]amino]oxane-3-carboxamide | Ki | 10000.0 [1] |
| (2S)-2-[[4-(4-Fluorophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 4800.0 [1] |
| (8S,11R,12S)-12-N-Hydroxy-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-11-[[4-[2-(trifluoromethyl)phenyl]phenyl]methyl]-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide | Ki | 834.0 [1] |
| N-Hydroxy-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide | IC50 | 2390.0 [1] |
| ((4'-Chloro-[1,1'-biphenyl]-4-yl)sulfonyl)valine | IC50 | 7500.0 [1] |
| (3S)-N-Hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamide | IC50 | 41.0 [1] |
| 2-Pyrimidinecarboxamide, hexahydro-N-hydroxy-1,3-bis((4-methoxyphenyl)sulfonyl)- | IC50 | 460.0 [1] |
| N-(4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl)acetamide | Ki | 39000.0 [1] |
| 4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl methanesulfonate | Ki | 18000.0 [1], 18200.0 [2] |
| N,6-Dihydroxy-2-(4-nitrophenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 21379.62 [1], 21420.0 [2] |
| N-[4-[2-(Hydroxyamino)-2-oxoethyl]oxan-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide | Ki | 25.0 [1] |
| (S)-N-Hydroxy-4-(4-methoxyphenylsulfonyl)-2,2-dimethyl-1,4-thiazepane-3-carboxamide | IC50 | 30.0 [1] |
| N-Hydroxy-4-(4-methoxyphenyl)sulfonylthiomorpholine-3-carboxamide | IC50 | 2027.0 [1], 2070.0 [2] |
| (7S,8R,11S)-7-N-Hydroxy-11-N-methyl-8-(2-methylpropyl)-9-oxo-2-oxa-10-azabicyclo[11.2.2]heptadeca-1(15),13,16-triene-7,11-dicarboxamide | IC50 | 1.6 [1] |
| 4-[(2-Methylquinolin-4-yl)methoxy]-N-[[5-(4-methylsulfonylpiperazin-1-yl)-2,4,6-trioxo-1,3-diazinan-5-yl]methyl]benzamide | Ki | 6370.0 [1] |
| 6-(Benzyloxy)-N-hydroxy-2-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 2398.83 [1], 2424.0 [2] |
| 4-((2-Methylquinolin-4-yl)methoxy)-N-(2-(2-oxo-2,3-dihydro-1H-imidazole-5-carbonyl)phenyl)benzamide | Ki | 636.0 [1], 6368.0 [2] |
| 4-[2-[[6-Fluoro-2-[(3-methoxyphenyl)methylcarbamoyl]-4-oxo-3H-quinazolin-5-yl]oxy]ethyl]benzoic acid | IC50 | 10000.0 [1] |
| 3-{[4-(But-2-Yn-1-Yloxy)phenyl]sulfonyl}propane-1-Thiol | Ki | 2500.0 [1] |
| (3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]benzoyl]amino]oxane-3-carboxamide | Ki | 6368.0 [1] |
| 5-(2-Amino-2-oxoethyl)-4-oxo-N-[(3-oxo-4H-1,4-benzoxazin-6-yl)methyl]-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidine-2-carboxamide | IC50 | 2500.0 [1], 10000.0 [2] |
| (8S,9R,12S)-8-N-Hydroxy-12-N-methyl-9-(2-methylpropyl)-10-oxo-2-oxa-11-azabicyclo[12.2.2]octadeca-1(16),14,17-triene-8,12-dicarboxamide | IC50 | 2.6 [1], 6.1 [2] |
| (2S,3R)-N-Hydroxy-3-(2-methylpropyl)-N'-[(2S)-1-(1,3-oxazol-2-yl)-1-oxo-3-phenylpropan-2-yl]-2-prop-2-enylbutanediamide | IC50 | 4.2 [1] |
| 6-(Benzyloxy)-N-hydroxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 12022.64 [1], 12040.0 [2] |
| 6-(Benzyloxy)-N-hydroxy-2-(phenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 7079.46 [1], 7136.0 [2] |
| N,6-Dihydroxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 10471.29 [1], 10500.0 [2] |
| N,6-Dihydroxy-7-methoxy-2-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 3162.28 [1], 3192.0 [2] |
| N,6-Dihydroxy-7-methoxy-2-(phenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 10690.0 [1], 10715.19 [2] |
| 2-(2,5-Dichlorophenylsulfonyl)-N,6-dihydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxamide | IC50 | 21379.62 [1], 21380.0 [2] |
| (6S,7S)-N-Hydroxy-5-methyl-6-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | IC50 | 5000.0 [1] |
| (6S,7S)-N-Hydroxy-5-methyl-6-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbonyl]-5-azaspiro[2.5]octane-7-carboxamide | Ki | 75.0 [1] |
| (2R,3R)-4-[(2R)-2-(3-Chlorophenyl)pyrrolidin-1-yl]-2,3-dihydroxy-4-oxo-N-[(1R)-1-(4-pyrazol-1-ylphenyl)ethyl]butanamide | Ki | 3769.0 [1], 3800.0 [2] |
| N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-[2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]amino]acetamide | Ki | 2000.0 [1] |
| (-)-Epigallocatechin gallate | IC50 | 21500.0 [1] |
| Ilomastat | IC50 | 33.0 [1] |
| N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid | Ki | 13000.0 [1] |
| (2S,3R)-N-Hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide | IC50 | 11.0 [1] |
| (S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid | IC50 | 7200.0 [1] |
| Epigallocatechin 3-O-(3-O-methyl)gallate | IC50 | 20000.0 [1] |
| Cipemastat | IC50 | 18.5 [1] |
| 2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide | IC50 | 100000.0 [1] |
| CID 9847838 | IC50 | 466.0 [1] |
| n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide | IC50 | 30.0 [1] |
| Unii-cdl03A411T | IC50 | 1000.0 [1] |
| (S)-4-(4'-Chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoic acid | IC50 | 10000.0 [1] |
| Unii-Q56UE7E40Y | IC50 | 5000.0 [1] |
| N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide | Ki | 4000.0 [1] |
| N-[(1S)-1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide | IC50 | 11000.0 [1] |
| (R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamide | IC50 | 11111.0 [1] |
| D-Tryptophan, N-[[5-[2-(4-methylphenyl)ethynyl]-2-thienyl]sulfonyl]- | IC50 | 1000.0 [1] |
| Methylamino-phenylalanyl-leucyl-hydroxamic acid | IC50 | 8.3 [1] |
| Grassystatin A | IC50 | 5000.0 [1] |
| (4S)-5-Amino-4-[[(2S)-2-[[(2S)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid | Ki | 626.0 [1] |
| 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione | IC50 | 50000.0 [1] |
| N-Phenyl-4-[(4h-1,2,4-Triazol-3-Ylsulfanyl)methyl]-1,3-Thiazol-2-Amine | IC50 | 10000.0 [1] |
| 2-(Biphenyl-4-ylsulfonamido)-N-hydroxyacetamide | Ki | 5000.0 [1] |
| 2-(Benzenesulfonamido)-N-hydroxyacetamide | Ki | 4000.0 [1] |
| N-Hydroxy-4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxamide | IC50 | 10000.0 [1] |
| (6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide | IC50 | 3.0 [1] |
| 4-Benzoyl-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 1522.0 [1] |
| (2R)-2-[[4-(4-Bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | IC50 | 11000.0 [1] |
| (2R)-2-[[4-(4-Bromophenyl)phenyl]sulfonylamino]-N-hydroxy-3-methylbutanamide | IC50 | 140.0 [1] |
| 4-[4-(Thiirane-2-ylmethylsulfonyl)phenoxy]phenol | Ki | 31000.0 [1] |
| (2R,3S)-2-[(4-But-2-ynoxyphenyl)sulfonylamino]-N,3-dihydroxybutanamide | IC50 | 961.0 [1] |
| (2S)-3-Methyl-2-[(4-phenylphenyl)sulfonylamino]butanoic acid | IC50 | 71000.0 [1] |
| (2S)-2-[[8-(Methoxycarbonylamino)dibenzofuran-3-yl]sulfonylamino]-3-methylbutanoic acid | IC50 | 22.0 [1] |
| 4''-Methylepigallocatechin gallate | IC50 | 72000.0 [1] |
| N-Hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonylpiperazine-2-carboxamide | IC50 | 232.0 [1] |
| Hydroxamate analogue 22 | IC50 | 180.0 [1] |
| 1-Cyclopropyl-N-hydroxy-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamide | IC50 | 7000.0 [1] |
| N-Hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide | IC50 | 10000.0 [1] |
| 1-Benzyl-4-(4-(4-chlorophenoxy)phenylsulfonyl)-N-hydroxypiperidine-4-carboxamide | IC50 | 925.0 [1] |
| MMP-9/MMP-13 Inhibitor I | IC50 | 931.0 [1] |
| 4-Acetyl-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 821.0 [1] |
| 4-(Furan-2-carbonyl)-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 642.0 [1] |
| 4-(Cyclohexanecarbonyl)-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 2173.0 [1] |
| N-Hydroxy-1-(4-methoxyphenylsulfonyl)-4-(2-phenoxyacetyl)piperazine-2-carboxamide | IC50 | 908.0 [1] |
| N-Hydroxy-1-(4-methoxyphenylsulfonyl)-4-(thiophene-2-carbonyl)piperazine-2-carboxamide | IC50 | 710.0 [1] |
| N-Hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)piperazine-2-carboxamide | IC50 | 22050.0 [1] |
| 4-Hexanoyl-N-hydroxy-1-(4-methoxyphenylsulfonyl)piperazine-2-carboxamide | IC50 | 787.0 [1] |
| L-Valine,N-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]- | IC50 | 5600.0 [1] |